肺泡蛋白沉积症的诊疗进展  

Progress in diagnosis and treatment of alveolar proteinosis

作　　者：常晓青 李丹丹[1] 胡莎莎 范儒旭 李英[1] Chang Xiao-Qing;Li Dan-Dan;Hu Sha-Sha;Fan Ru-Xu;Lee Ying(Department of Respiratory and Critical Care Medicine,People's Hospital of Henan University,Zhengzhou 450003,China)

机构地区：[1]河南大学人民医院呼吸与危重症医学科,河南郑州450003

出　　处：《四川生理科学杂志》2024年第4期940-944,共5页Sichuan Journal of Physiological Sciences

摘　　要：肺泡蛋白沉积症是一种罕见的肺部疾病,其表面活性物质在肺泡巨噬细胞和远端气道积聚,导致气体交换受损,从而引起呼吸困难和低氧血症。自1958年首次报告以来,临床对该疾病的发病机制、诊断、治疗等方面的认识有很大进展。本文主要就肺泡蛋白沉积症的发病机制、诊断、治疗进行综述。Alveolar proteinosis is a rare lung disease in which surfactant accumulation in alveolar macrophages and distal airways leads to impaired gas exchange,resulting in dyspnea and hypoxemia.Since the first report in 1958,the clinical understanding of the pathogenesis,diagnosis and treatment of the disease has made great progress.This article reviews the pathogenesis,diagnosis and treatment of alveolar proteinosis.

关 键 词：肺泡蛋白沉积症 发病机制 诊疗进展 

分 类 号：R563[医药卫生—呼吸系统]